IsoPlexis Wins $4M SBIR Grant From NCI

Jun 21, 2019

|

NEW YORK (GenomeWeb) – Single-cell proteomics firm IsoPlexis said today that it has received a $4 million Small Business Innovation Research (SBIR) grant from the National Cancer Institute.

The Branford, Connecticut-based company said that it will use the funds to commercialize its IsoLight platform for use in quality control and guidance of CAR T therapy.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Featured White Papers

Novel Artificial Intelligence (AI)-based Technology to Improve Oncology Clinical Trial Fulfillment

Circulating Protein Biomarkers are a Promising Avenue for Predicting Patient Response to Cancer Immunotherapies

Seeing Beyond the Limit: Detect Residual Disease and Assess Treatment Response

A Personalized, Tumor-Informed Approach to Detect Molecular Residual Disease With High Sensitivity and Specificity

Oct

08

Featured Webinar

Novel Applications of RNA-based Precision Oncology: From Drug Tolerability to Immunogenomics

This webinar, Part 3 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss novel and emerging applications of RNA-based genomic analysis in precision oncology, form characterizing the tumor microenvironment to informing the development of immuno-oncology treatments.

Oct

14

Featured Webinar

Application of ctDNA Analysis to Detect MRD and Predict Recurrence in Colorectal Cancer

Circulating tumor DNA (ctDNA) can allow clinicians and researchers to better understand which patients are at high risk of recurrence and should be offered intensified chemotherapy or selected for clinical trials.

Oct

15

Featured Webinar

A Comparison of cfDNA Approaches to Guide Targeted Therapy in NSCLC

In non-small cell lung cancer (NSCLC), early detection of emerging resistance mutations such as EGFR T790M is important in order to determine the appropriate targeted therapeutic strategy.

Oct

27

Featured Webinar

The Promise of Liquid Biopsy for Cancer Diagnostics and Therapeutic Monitoring: Are We There Yet?

This webinar brings together an expert panel of stakeholders in cancer diagnostics and clinical care who will discuss the promise and challenges of liquid biopsy technologies in cancer diagnosis, monitoring, and patient care management.

Menu

IsoPlexis Wins $4M SBIR Grant From NCI

To read the full story....

Breaking News

Calithera Biosciences Begins Phase II Lung Cancer Trial of Telaglenastat Plus Chemo, Immunotherapy

Ideaya, Pfizer Expand Collaboration to Study IDE196, Xalkori

Lantern Pharma, Fox Chase Partner on Pancreatic Cancer Drug, Search for Predictive Gene Signature

FDA Accepts Pfizer's sNDA for Xalkori in Rare ALK-Positive Pediatric Leukemia Indication

Novellus Raises $57M in Series C Funding

Metastatic Cancer Treatment Markers Identified in Clinical WGS Study

Featured White Papers

Novel Applications of RNA-based Precision Oncology: From Drug Tolerability to Immunogenomics

Application of ctDNA Analysis to Detect MRD and Predict Recurrence in Colorectal Cancer

A Comparison of cfDNA Approaches to Guide Targeted Therapy in NSCLC

The Promise of Liquid Biopsy for Cancer Diagnostics and Therapeutic Monitoring: Are We There Yet?

What's Popular?

Oncology Venture Becomes Allarity Therapeutics, Announces Board, Executive Changes

Merck's Keytruda, BMS's Opdivo Prolong Survival for Patients With Gastroesophageal Cancers

Metastatic Cancer Treatment Markers Identified in Clinical WGS Study

Roche's Ipatasertib, Anti-Androgen Therapy Improves Outcomes in Prostate Cancer With PTEN Loss

Agios's Tibsovo Trial Fails to Meet Overall Survival Endpoint in IDH1-Mutated Bile Duct Cancer

Sponsorships